The role of insulin, growth hormone and IGF-I as anabolic agents in the critically ill.
Ross
R J
RJ
Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Rodriguez-Arnao
J
J
Bentham
J
J
Coakley
J H
JH
D000818:Animals; D002352:Carrier Proteins / Q000502:physiology; D016638:Critical Illness; D013006:Growth Hormone / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use*; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use*; D009102:Multiple Organ Failure / Q000188:drug therapy* / Q000378:metabolism*; D017526:Receptor, IGF Type 1 / Q000145:classification / Q000187:drug effects; D013002:Somatomedins / Q000502:physiology
D002352:Carrier Proteins; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D013002:Somatomedins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D017526:Receptor, IGF Type 1